ACRIVON THERAPEUTICS INC (ACRV) Stock Price, Quote, News and Overview
NASDAQ:ACRV - Nasdaq - US0048901096 - Common Stock - Currency: USD
ACRV Quote, Performance and Key Statistics
1.2
-0.07 (-5.51%)
The current stock price of ACRV is 1.2 USD. In the past month the price increased by 9.09%. In the past year, price decreased by -83.45%.
ACRV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.61 | 337.52B | ||
| AMGN | AMGEN INC | 14.22 | 158.74B | ||
| GILD | GILEAD SCIENCES INC | 14.21 | 136.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.94 | 57.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
| ARGX | ARGENX SE - ADR | 100.5 | 35.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.89 | 29.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.62B | ||
| NTRA | NATERA INC | N/A | 22.58B | ||
| BIIB | BIOGEN INC | 8.26 | 19.14B | ||
| INSM | INSMED INC | N/A | 17.98B |
Related stock screener links
About ACRV
Company Profile
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. The company is headquartered in Watertown, Massachusetts and currently employs 75 full-time employees. The company went IPO on 2022-11-15. The company uses its precision Generative Phosphoproteomics platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a registrational Phase II trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore improve the clinical overall response rate (ORR) and has the potential to enable drug development. Its preclinical program, ACR-2316, is advancing in investigational new drug-enabling studies. The company is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.
Company Info
ACRIVON THERAPEUTICS INC
480 Arsenal Way, Suite 100
Watertown MASSACHUSETTS US
Employees: 60
Phone: 16172078979
ACRIVON THERAPEUTICS INC / ACRV FAQ
What is the stock price of ACRIVON THERAPEUTICS INC today?
The current stock price of ACRV is 1.2 USD. The price decreased by -5.51% in the last trading session.
What is the ticker symbol for ACRIVON THERAPEUTICS INC stock?
The exchange symbol of ACRIVON THERAPEUTICS INC is ACRV and it is listed on the Nasdaq exchange.
On which exchange is ACRV stock listed?
ACRV stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACRIVON THERAPEUTICS INC stock?
15 analysts have analysed ACRV and the average price target is 10.93 USD. This implies a price increase of 810.72% is expected in the next year compared to the current price of 1.2. Check the ACRIVON THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACRIVON THERAPEUTICS INC worth?
ACRIVON THERAPEUTICS INC (ACRV) has a market capitalization of 37.63M USD. This makes ACRV a Nano Cap stock.
How many employees does ACRIVON THERAPEUTICS INC have?
ACRIVON THERAPEUTICS INC (ACRV) currently has 60 employees.
What are the support and resistance levels for ACRIVON THERAPEUTICS INC (ACRV) stock?
ACRIVON THERAPEUTICS INC (ACRV) has a resistance level at 1.24. Check the full technical report for a detailed analysis of ACRV support and resistance levels.
Should I buy ACRIVON THERAPEUTICS INC (ACRV) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACRV, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACRV, evaluating the profitability, health, valuation and growth aspects
- ACRIVON THERAPEUTICS INC (ACRV) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACRIVON THERAPEUTICS INC (ACRV) Sales and EPS estimates to see what analysts future expectations are.
- ACRIVON THERAPEUTICS INC (ACRV) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACRIVON THERAPEUTICS INC (ACRV) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACRIVON THERAPEUTICS INC (ACRV) Stock Chart to make your own analysis
- ACRIVON THERAPEUTICS INC (ACRV) Latest news and press-releases to stay up to date.
Does ACRIVON THERAPEUTICS INC (ACRV) stock pay dividends?
ACRV does not pay a dividend.
What is the Price/Earnings (PE) ratio of ACRIVON THERAPEUTICS INC (ACRV)?
ACRIVON THERAPEUTICS INC (ACRV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.22).
What is the Short Interest ratio of ACRIVON THERAPEUTICS INC (ACRV) stock?
The outstanding short interest for ACRIVON THERAPEUTICS INC (ACRV) is 5.96% of its float. Check the ownership tab for more information on the ACRV short interest.
ACRV Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ACRV. When comparing the yearly performance of all stocks, ACRV is a bad performer in the overall market: 99.37% of all stocks are doing better.
ACRV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACRV. ACRV has a great financial health rating, but its profitability evaluates not so good.
ACRV Financial Highlights
Over the last trailing twelve months ACRV reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS increased by 22.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47.49% | ||
| ROE | -52.22% | ||
| Debt/Equity | 0 |
ACRV Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ACRV. The Buy consensus is the average rating of analysts ratings from 15 analysts.